Heart Institute, Hadassah Medical Center, Jerusalem, Israel; Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Jesselson Integrated Heart Center, Shaare Zedek Medical Center, Jerusalem, Israel; Faculty of Health Sciences, Ben Gurion University of the Negev, Beer-Sheva, Israel.
JACC Clin Electrophysiol. 2022 Jul;8(7):918-936. doi: 10.1016/j.jacep.2022.04.013. Epub 2022 Apr 28.
Idiopathic ventricular fibrillation is responsible for approximately 5%-7% of cases of aborted cardiac arrest. Recent studies have shown that short-coupled ventricular premature complexes are present at the onset of idiopathic ventricular fibrillation in 6.6%-17% of patients. The present review provided information on 86 patients with short-coupled malignant ventricular arrhythmias that were reported as case reports or small patient series during the last 70 years. In 75% of the 81 cases published during the last 40 years, extended information and follow-up (from 2.63 ± 4.5 years to 10.67 ± 7.8 years; P < 0.001, between the original publication to the latest update) could be obtained from the authors. The review shows that short-coupled malignant ventricular arrhythmias occurred almost equally in males and females, at the mean age of 40 years. A tendency for later occurrence of the arrhythmia by 4 years was observed in females. A prior history of syncope was noted in 45.3% of the patients, whereas arrhythmic storm occurred in 42% at presentation. The most common mode of revelation of short-coupled malignant ventricular arrhythmias was syncope (53.5%), followed by aborted cardiac arrest (26.7%) and recurrent arrhythmic event after prior implantable-cardioverter defibrillator implantation for idiopathic ventricular fibrillation (17.4%). For the first time, short-coupled malignant arrhythmias exhibiting "not-so-short" coupling intervals (≥350 milliseconds) were found in a significant proportion of patients (17.4%). During long-term follow-up, quinidine yielded a slightly higher success rate in arrhythmia control than ablation. Larger studies are necessary to assess the best strategy for the management of this potentially lethal arrhythmia.
特发性室颤约占心搏骤停中止病例的 5%-7%。最近的研究表明,6.6%-17%的特发性室颤患者在室颤起始时存在短联律间期室性早搏。本综述提供了过去 70 年来 86 例短联律恶性室性心律失常患者的信息,这些患者为病例报告或小患者系列。在过去 40 年发表的 81 例中有 75%,作者可以提供扩展信息和随访(从 2.63±4.5 年到 10.67±7.8 年;P<0.001,从原始出版物到最新更新)。综述显示,短联律恶性室性心律失常在男性和女性中的发生率几乎相等,平均年龄为 40 岁。女性心律失常的发生时间平均延迟 4 年。45.3%的患者有晕厥史,42%的患者在就诊时发生心律失常风暴。短联律恶性室性心律失常最常见的揭示方式是晕厥(53.5%),其次是心搏骤停中止(26.7%)和先前因特发性室颤植入植入式心律转复除颤器后反复发作心律失常(17.4%)。首次发现,相当比例的患者(17.4%)存在“非短”联律间期(≥350 毫秒)的短联律恶性心律失常。在长期随访中,奎尼丁在控制心律失常方面的成功率略高于消融。需要更大规模的研究来评估这种潜在致命性心律失常的最佳治疗策略。